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Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant compar-
ators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-
NETs) and the pancreas (P-NETs).
Materials and methods: A three-state partitioned survival model was developed to perform a
cost-utility analysis of [177Lu]Lu-DOTA-TATE versus standard of care (high dose Octreotide
LAR), everolimus and sunitinib. Effectiveness data for SoC, everolimus and sunitinib were
obtained from published KaplaneMeier survival curves. Given a lack of head-to-head
effectiveness data, matching adjusted indirect comparisons (MAICs) were performed to
population-adjust [177Lu]Lu-DOTA-TATE survival data based on prognostic factors and
derive estimates of relative effectiveness. Health state utilities were estimated from real-
world evidence. Drug acquisition costs were taken from nationally published sources
(BNF, NICE), and administration costs were based on treatment protocols in [177Lu]Lu-
DOTA-TATE studies, combined with nationally published unit costs (PSSRU, DoH reference
costs). Incidence of adverse events were estimated using published sources. A discount
rate of 3.5% was applied to both utilities and costs, and deterministic and probabilistic
sensitivity analyses were performed. Costs were included from an NHS perspective and
presented in 2017/18 GBP (and PPP Euros for base case).
Results: In GI-NETs, the incremental cost-effectiveness ratio (ICER) of [177Lu]Lu-DOTA-TATE
compared to SoC and everolimus was £26,528 (V27,672) and £24,145 (V25,186) per QALY,
respectively. In P-NETs, the ICER of [177Lu]Lu-DOTA-TATE compared to SoC was £22,146
(V23,101) or £28,038 (V29,251) dependent on matched population, and £21,827 (V22,766) and
£15,768 (V16,445) compared to everolimus and sunitinib, respectively.
Conclusions: At a willingness to pay threshold of £30,000, [177Lu]Lu-DOTA-TATE is likely to
be a cost-effective treatment option for GI-NET and P-NET patients versus relevant treat-
ment comparators (NHS perspective).
© 2021 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).artis.com (O.R. Leeuwenk
his is an open access artamp).
icle under the CC BY-NC-ND license (http://creativecommons.org/
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Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
are a heterogeneous group of tumours originating in neuro-
endocrine cells of the gastrointestinal tract (GI-NETs) or
pancreas (P-NETs) [1]. To date, the only curative treatment for
GEP-NETs is surgery of resectable and localised tumours. In
patients who are ineligible for surgery, targeted ablation
therapies and transarterial embolisation can achieve regional
control of liver metastases [2]. In patients with advanced,
unresectable GEP-NETs, therapeutic options are limited, with
somatostatin analogues (e.g. Octreotide LAR (Sandostatin®;
Novartis International AG), Somatuline Autogel often used as
best supportive care to limit symptoms and, in recent times,
they have been shown to have some anti-tumour benefit [3,4].
Two biologically targeted therapies, everolimus (Afinitor®;
Novartis International AG) and sunitinib (Sutent®; Pfizer Inc.)
were approved in 2011 for the treatment of patients with
advanced, progressive, well-differentiated P-NETs changing
the treatment paradigm. Chemotherapy is usually reserved
for high-grade progressive NETs but historically, streptozocin
regimens have been utilised for advanced well-differentiated
P-NETs and more recently temozolomide regimens for P-
NETs. There is very little role for chemotherapy in well-
differentiated GI-NETs. [177Lu]Lu-DOTA-TATE (Lutathera®;
Advanced Accelerator Applications), a peptide receptor
radionuclide therapy (PRRT) that selectively targets somato-
statin receptors, received marketing authorisation for the
treatment of GEP-NETs in 2017, with orphan designation from
the European Medicines Agency (EMA) [5].
In addition to demonstrating clinical effectiveness, cost-
effectiveness of new treatments plays a pivotal role in the
decision-making process overseen by the National Institute of
Health and Care Excellence (NICE) in England. A de novo par-
titioned survival model was constructed to evaluate the cost-
effectiveness of [177Lu]Lu-DOTA-TATE for the NHS in England
for the treatment of GEP-NETs. This paper details the struc-
ture, input parameters, and results of the model, including
consideration of uncertainty in modelled outputs.2. Methods
The model reflects a population of adult patients with inop-
erable, progressive GEP-NETs. In this analysis, the GEP-NET




GI-NETs and P-NETs 4 administrations of 7.
weeks [28]
Standard of care (SoC) GI-NETs and P-NETs 60 mg Octreotide LAR
cycle
Everolimus (Afinitor®) GI-NETs and P-NETs 10 mg administered on
Sunitinib (Sutent®) GI-NETs and P-NETs 37.5 mg administered
GI-NETs, neuroendocrine tumours located in the gastrointestinal tract; PNETs to reflect different effectiveness data and comparators.
Most patients would have initially been treated first-line with
somatostatin analogues and, thus, [177Lu]Lu-DOTA-TATE is
usually used as a second- or third-line therapy. In the GI-NET
patient subpopulation, [177Lu]Lu-DOTA-TATE was compared
to standard of care (SoC), consisting of increased dose
octreotide, and everolimus; and in the P-NET patient sub-
population, [177Lu]Lu-DOTA-TATE was compared to SoC,
everolimus and sunitinib. It should be noted that everolimus
is only indicated in non-functional GI-NETs and P-NETs and
sunitinib solely for P-NETs [6,7].
Evidence for the efficacy of [177Lu]Lu-DOTA-TATE was
derived from the ERASMUS single arm study for both GI-NET
and P-NET patients and data in GI-NETs for everolimus and
SoC were derived from the RADIANT-4 study [8,9]. For ever-
olimus and SoC, data in P-NETs were derived from the
RADIANT-3 study [10,11] and for sunitinib, data from
NCT00428597 trial [12,13] were used.
The model comprises effectiveness, health-related quality
of life (HRQoL) and cost data to perform a cost-utility analysis.
Outcomes are presented as the cost per quality-adjusted life-
years (QALYs).2.1. Intervention and comparators
A summary of intervention and comparator regimen included
in the analysis is presented in Table 1.2.2. Model structure
The model structure is illustrated in Fig. 1. In a partitioned
survival model, survival is separated into distinct health
states, which are associated with state specific estimates of
HRQoL and/or costs. In oncology trials, progression-free sur-
vival (PFS) and overall survival (OS) constitute common study
endpoints that are routinely collected, which can be used to
construct partitioned survival models [14]. A partitioned
approach was favoured over a state transition approach pri-
marily because it enables the use of comparator trials where
only aggregate level survival data are available from published
KaplaneMeier curves [15].
The model health states were defined as
1. Progression-free survival: PFS(t) ¼ P(PFS  t)
2. Post-progression survival: PPS(t) ¼ P(OS  t)  P(PFS  t)
3. Death: D(t) ¼ 1  P(OS  t)Regimen Price
4 GBq (200 mCi), once every 8 29.6 GBq (800 mCi) ¼ £71,500
(Sandostatin®), once every 28-day 30 mg vial ¼ £998.41
ce daily, until progression [6] 30-tab, 10 mg packs ¼ £2673
once daily, until progression [7] 30-tab, 12.5 mg packs ¼ £784.70
-NETs, neuroendocrine tumours located in the pancreas.
e j c s u p p l em en t s 1 6 ( 2 0 2 1 ) 1 4e2 316The modelled cohort starts in the progression-free state at
year time zero. State membership is determined by PFS and
OS curves, estimated using parametric models fitted to
patient-level data (PLD) or KaplaneMeier data. The proportion
of the cohort in the progression-free state is determined by
the PFS curve. The proportion of the cohort in the death state
equals 1, minus the survival probability associated with the
OS curve at any given time interval. The difference between
the PFS curve and OS curves yields the proportion of modelled
cohort in the post-progression state in any given time interval.
Therefore, PFS and OS are implicitly modelled independently.
Explored parametric fits included Weibull, Gompertz,
lognormal and exponential. Clinical plausibility, visual in-
spection and AIC/BIC were used to determine the most
appropriate parametric curves.
Specific estimates of HRQoL and backgroundmedical costs
were attributed progression-free and post-progression health
states reflective of severity of symptoms experienced by pa-




The pivotal Phase III (NETTER-1) clinical trial showed
increased progression-free and overall survival in the [177Lu]
Lu-DOTA-TATE arm compared to Octreotide LAR (60 mg) [16].
However, this trial only involved GI-NET patients with midgut
NETs and does not allow for direct comparisons with other
potentially relevant treatments, which have emerged in
recent years.
The investigator-sponsored single-arm study ERASMUS
provides an additional source for effectiveness data. This
study was conducted at the Erasmus Medical Centre, Rotter-
dam, Netherlands, evaluating the efficacy of [177Lu]Lu-DOTA-
TATE administered intravenously to patients with
somatostatin receptorepositive tumours [9]. The study con-
stitutes the longest available follow-up data of patients
undergoing treatment with [177Lu]Lu-DOTA-TATE and
included patients with GI-NET and P-NETs, with a high pro-
portion of patients with observed PFS and OS events. How-
ever, this study does not contain a control arm; it was,
therefore, necessary to perform indirect comparisons.Fig. 1 e Partitioned survival mTwomatching adjusted indirect comparisons (MAICs) were
performed for GI-NET and P-NET patient populations using
patient-level data (PLD) from the ERASMUS study for [177Lu]
Lu-DOTA-TATE, published data from the RADIANT-4 [8] (GI-
NETs) and RADIANT-3 [11] (P-NETs) trials for everolimus, and
published data from the NCT00428597 trial for sunitinib [12].
Full details of these methods have been published previously
(refer to MAIC publication). In brief, patient-level data from
ERASMUS were reweighted based on prognostic factors and
effect modifiers of survival, identified through engagement
with clinicians, published literature and empirical investiga-
tion of the relationships in the ERASMUS PLD (age, gender,
ECOG, previous radiotherapy and previous chemotherapy).
This reweighting procedure produced survival data based on
a population matched to the patient population in the
comparator trials, for which only aggregate data were avail-
able. For OS comparisons in GI-NET, comparator data were
only available in a GI-NET and lung NET population. To avoid
potential bias from matching to this population, post-
progression survival was assumed to be the same in SoC
and everolimus arms as in [177Lu]Lu-DOTA-TATE, in line with
the approach suggested by Hoyle and colleagues [17].
After reweighting survival outcomes, parametric time-to-
event curves were fitted, mainly to extrapolate beyond the
duration of the comparator randomised trials until the time
horizon of the cost-effectiveness analysis. Parametric curves
were preferred over reweighting, as this can produce long tails
in KaplaneMeier survival curves. Of these, the Weibull curve
generally provided best fit to the observed data visually and
based on AIC and BIC, except in the comparison versus suni-
tinib (see supplementary data Table A1.7). The Weibull curve
was operationalised with functional form S (t) ¼ exp {(lt) b}
where S ¼ survival; t ¼ time (interval); l ¼ location (scale);
b ¼ shape. The exponential curve was implemented as S
(t)¼ exp {(at)}, where: S¼ survival; t¼ time (interval); a¼ rate
parameter. Full parameterisation of the survival curves is
given in supplementary data Table A1.1 to A1.6.
2.3.2. Adverse events
All active comparators are associated with an incidence of
adverse events. These events may have both HRQoL and cost
implications. Data were taken from clinical trials according to
individual trial reporting criteria, accounting for more severe,odel structure (stylised).
Table 2 e Drug administration costs.
Resource use item Frequency Unit Costs (SE) Source Notes
Lutathera®
Physicist 30 min used in preparation
of Lutathera®
£53 (53) PSSRU Band 7 hospital based
professional per hour
Consultant 15 min, administering
Lutathera® and
concomitant treatment
£108 (108) PSSRU General medicine
consultant per hour
Radiographer 1.5 h for preparation
and administration of Lutathera®









Day ward nurse 30 min, administering
Octreotide LAR
£37 (37) NHS reference costs
2017/18
Band 5 Nurse per hour
Outpatient day attendance 0 h for administering
Octreotide LAR
£698 (698) NHS reference costs
2017/18
Day case- assumed 12 h
admission
Table 3 e Monitoring costs.
Resource use item Frequency Unit cost (SE) Source
CT/MRI Every 12 weeks £122.91 NHS reference costs 2017/18 [19]
ECG Every 8 weeks £107.84 NHS reference costs 2017/18 [19]
CBC with differential Every 4 weeks £2.51 NHS reference costs 2017/18 [19]
Blood chemistry screen Every 4 weeks £2.51 NHS reference costs 2017/18 [19]
Urinalysis Every 4 weeks £1.11 NHS reference costs 2017/18 [19]
e j c s u p p l em en t s 1 6 ( 2 0 2 1 ) 1 4e2 3 17at least grade III adverse events likely to have a HRQoL impact
and/or cost consequence. Full details of adverse events and
cost and utilities applied in the cost-effectiveness analysis are
shown in supplementary data Table A2.1 to A2.2.
Given incidences are expressed as a proportion of patients
experiencing adverse events during a specified treatment
period, and assuming a patient is likely to only experience one
of each of these events, costs and disutilities were accounted
for in the first modelled interval.Table 5 e GI-NET results: [177Lu]Lu-DOTA-TATE versus SoC, [17
Treatment modalities Costs QALYs Incremental costs
SoC £67,454 2.94
[177Lu]Lu-DOTA-TATE £100,073 4.17 (V34,040)
Everolimus £74,687 3.1
[177Lu]Lu-DOTA-TATE £100,584 4.17 (V27,015)
GI-NETs, neuroendocrine tumours located in the gastrointestinal tract;
quality-adjusted life-years.
P stands for probability, SoC for standard of care and WTP for Willingness
based on Purchasing Power Parity rates.
Table 4 e Partitioned health state utility values.
Health state GI-NET utility value (95%
CI)
Sour
Progression-free 0.793 (0.771e0.815) RWE [23
Post-progression 0.740 (0.721e0.759) ERASMU
Death 0 Assump
GI-NETs, neuroendocrine tumours located in the gastrointestinal tract; P2.3.3. Resource use and unit costs
Costs accounted for in the model were drug acquisition costs,
drug administration costs, monitoring costs, costs of man-
aging adverse events, and costs of palliative care (included in a
scenario analysis). All costs are presented in 2017/18 prices.
Where necessary, unit costswere inflated using PSSRU indices
[18].
NETTER-1 and ERASMUS studies informed resources used
to administer octreotide LAR and [177Lu]Lu-DOTA-TATE. Cost7Lu]Lu-DOTA-TATE versus everolimus.
Incremental QALYs ICER (cost/QALY) P (cost-effective)
at WTP £30,000
1.23 £26,528 (V27,672) 77%
1.07 £24,145 (V25,186) 88%
P-NETs, neuroendocrine tumours located in the pancreas; QALYs,
to Pay. In brackets the ICER values are provided for the costs in euros
ce P-NET utility value (95%
CI)
Source
] 0.805 (0.793e0.816) ERASMUS [25]
S [25] 0.790 (0.758e0.823) ERASMUS [25]
tion 0 Assumption
-NETs, neuroendocrine tumours located in the pancreas.
Table 6 e P-NET results: [177Lu]Lu-DOTA-TATE versus SoC, [177Lu]Lu-DOTA-TATE versus everolimus, [177Lu]Lu-DOTA-
TATE versus sunitinib.
Treatmentmodalities Costs QALYs Incremental costs Incremental
QALYs
ICER (cost/QALY) P (cost-effective)
at WTP £30,000
SoC (RADIANT-3) £60,326 3.12
[177Lu]Lu-DOTA-TATE £111,289 4.94 £50,963 (V53,169) 1.82 £28,038 (V29,251) 65%
SoC (NCT00428597) £53,033 2.96
[177Lu]Lu-DOTA-TATE £118,525 5.64 £65,491 (V68,315) 2.96 £22,146 (V23,101) 99%
Everolimus £72,497 3.25
[177Lu]Lu-DOTA-TATE £113,103 5.11 £40,606 (V42,352) 1.86 £21,827 (V22,766) 96%
Sunitinib £81,350 3.55
[177Lu]Lu-DOTA-TATE £117,915 5.87 £36,617 (V38,135) 2.32 £15,768 (V16,445) 100%
GI-NETs, neuroendocrine tumours located in the gastrointestinal tract; P-NETs, neuroendocrine tumours located in the pancreas; QALYs,
quality-adjusted life-years.
P stands for probability, SoC for standard of care and WTP for Willingness to Pay.
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ographer, consultant time and an overnight stay (c. 90% are
overnight, even though it is possible to perform as a day case)
were estimated for Lutathera administration. Drug acquisi-
tion costs were taken from the British National Formulary
(BNF) or manufacturers list price indicated in NICE guidance
(see Table 1 and supplementary data Table A2.3). Only
Octreotide LAR in-hospital along side [177Lu]Lu-DOTA-TATE
and [177Lu]Lu-DOTA-TATE were assumed to have adminis-
tration costs, the other treatments being oral medication with
assumed use in an out-patient setting.
Monitoring resource use was based on NETTER-1 protocol,
and unit costs were taken from Department of Health (DoH)
NHS Reference Costs (2017/18) [19], see Table 3. Adverse event
unit costs were also sourced from NHS Reference Costs, with
associated resource use inferred from Common Terminology
Criteria for Adverse Events (CTCAE) grading guidance notes
[20]. It was assumed that grade IIIeV events would require a
short stay hospital admission, except in the case of blood cell
count events (neutropenia, lymphocyte count disease, lym-
phopenia) and asthenia/fatigue which were assumed to resultFig. 2 e Tornado diagram: P-NET [177Lu]Lu-DOTA-TATE versus
located in the pancreas.in an outpatient attendance (see supplementary data Table
A2.2).
To provide a benchmark and aid cross-country compari-
sons, costs were converted into Euros using purchasing power
parity rates for the UK and Euro Area [21]. Base case results
were presented in Euros (V) alongside cost-effectiveness
expressed in GBP (£) (see Tables 5 and 6).
2.3.4. Utilities
The European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)
instrument [22] was used to collect QoL data directly from
patients in the NETTER-1 and ERASMUS studies. A further
source of UK-specific real-world evidence (RWE) was identi-
fied from EORTC data collected at St Guys and Thomas's
Hospital (London, UK), a large centre treating UK GEP-NET
cases [23]. However, the EORTC QLQ-C30 does not explicitly
provide utility values required to compute QALYs. Data
collected in these three studies were mapped to the EQ-5D-3L
for use in the cost-effectiveness model using the algorithm
published by Longworth et al. [24].SoC - RADIANT-3 MAIC. P-NETs, neuroendocrine tumours
Fig. 3 e Tornado diagram: P-NET [177Lu]Lu-DOTA-TATE versus everolimus. P-NETs, neuroendocrine tumours located in the
pancreas.
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HRQoL in the GI-NET population. Given the data collection
points and time until progression in these studies, post-
progression utility data were only available for a small num-
ber of patients (<5) in the NETTER-1 study or RWE. HRQoL data
for GI-NET patients in the ERASMUS study were therefore
used for the post-progression health state in the model. For P-
NETs, the Erasmus dataset constituted the largest source of P-
NET-specific HRQoL data [25]. Health state utility values used
in the model are shown in Table 4.
A disutility associated with each of the adverse events was
applied in the relevant model arm. Disutilities were sourced
through a pragmatic literature review, or obtained fromFig. 4 e Tornado diagram: P-NET [177Lu]Lu-DOTA-TATE versus S
located in the pancreas.previous NICE technology appraisals, as shown in
supplementary data Table A2.2.
2.4. Cost-effectiveness analysis
The cost-utility analysis was operationalised in Microsoft
Excel©, with intervals of a month for the partitioned survival
model. A discount rate of 3.5%was applied to both utilities and
costs in line with UK recommendations [26], with half-cycle
correction using a life table approach [27]. The model was
run for a time horizon of 20 years approximating a lifetime
analysis, given the average cohort age of 63.7 years at the start
of the model.oCeNCT00428597 MAIC. P-NETs, neuroendocrine tumours
Fig. 5 e Tornado diagram eP-NET [177Lu]Lu-DOTA-TATE versus sunitinib. P-NETs, neuroendocrine tumours located in the
pancreas.
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lower and upper bounds informed by 95% confidence in-
tervals, or a wide interval used (±10% or 25%). Five thousand
iterations were run to conduct probabilistic sensitivity anal-
ysis (PSA), with Gamma distributions used for costs and Beta
distribution for utilities and relative dose intensity. Where an
appropriatemeasure of dispersionwas not available, standard
error was assumed equal to the mean value. Survival proba-
bilities at any given time interval were drawn from appro-
priate variance covariance matrices, calculated using the
Cholesky decomposition. Results are presented as an incre-
mental cost-effectiveness ratio (ICER), with associated prob-
ability of [177Lu]Lu-DOTA-TATE being cost-effective at a
willingness to pay threshold of £30,000 per QALY.Fig. 6 e Cost-effectiveness plane (CEP)eGI-NET [177Lu]Lu-DOTA-T
in the gastrointestinal tract.3. Results
The cost-effectiveness results for GI-NETs and P-NETs are
shown in Tables 5 and 6, respectively. For all comparisons,
[177Lu]Lu-DOTA-TATE produced additional QALYs at an addi-
tional cost. The health benefit ranged from 1.07 to 2.96 QALYs,
with incremental costs ranging from £25,896 (V27,015) to
£65,491 (V68,315) translating into ICERs between £15,768
(V16,445) and £28,038 (V29,251) per QALY gained (Tables 5 and
6).
Results of one-way sensitivity analysis for P-NETs are
shown in Tornado diagrams (Figs. 2e5) and demonstrate that
the ICER is most sensitive to the relative dose intensity of
[177Lu]Lu-DOTA-TATE and to a lesser extent to health stateATE versus SoC. GI-NETs, neuroendocrine tumours located
Fig. 7 e Cost-effectiveness Acceptability Curve (CEAC) e GI-NET [177Lu]Lu-DOTA-TATE versus everolimus. GI-NETs,
neuroendocrine tumours located in the gastrointestinal tract,
e j c s u p p l em en t s 1 6 ( 2 0 2 1 ) 1 4e2 3 21utility values. In GI-NET and P-NET analyses, results were
robust to changes in input parameters, with most ICERs
remaining below £30,000 and the highest ICER being £30,469.
When all input parameter uncertainty is jointly consid-
ered, probabilistic sensitivity analyses suggest a high likeli-
hood that [177Lu]Lu-DOTA-TATE is cost-effective at a
willingness to pay threshold of £30,000 per QALY and proba-
bility of [177Lu]Lu-DOTA-TATE being cost-effective in P-NETs
ranged from 65% compared with SoC to 100% compared to
sunitinib. The respective probability of [177Lu]Lu-DOTA-TATE
being cost-effective in GI-NETs was 77% compared with SoC
and 88% compared to everolimus (CEP versus SoC and CEAC
versus everolimus) (see Figs. 6 and 7).4. Discussion
Demonstrating cost-effectiveness constitutes an important
aspect of reimbursement for multiple decision-making bodies
worldwide, including NICE. Cost-effectiveness analyses for
[177Lu]Lu-DOTA-TATE were performed using a partitioned
survival model, reflecting PFS and OS [15]. Analyses demon-
strate cost-effectiveness of [177Lu]Lu-DOTA-TATE at a will-
ingness to pay threshold of £30,000 per QALY for all GI-NET
and P-NET model comparators and at a threshold of £20,000
per QALY in P-NET versus sunitinib, with all results robust to
uncertainty and changes in model inputs. This is the first
study to present data on the cost-effectiveness of [177Lu]Lu-
DOTA-TATE relating to the UK.
It should, however, be noted that heterogeneity of trials
included in the conducted MAIC partly contributed to the
uncertainty of derived relative efficacies. Furthermore, no
overall survival data were available for GI-NET in RADIANT-4
(it included lung NET patients in addition to GI-NET). In line
with Hoyle et al. [17], post-progression was assumed equal to
that of [177Lu]Lu-DOTA-TATE for SoC and everolimus. MAICs,
especially those based on single-arm unanchored compa-risons require multiple assumptions, whereby all variation in
survival outcomes is assumed to be accounted for by included
covariates, which is rarely likely to be the case. Matching of
study populations in terms of prognostic factorsmay also lead
to a substantial decrease in effective sample size.
The modelling approach detailed in this paper formed the
basis of the manufacturer submission for the NICE Tech-
nology Appraisal TA539 which resulted in a positive
recommendation, subject to a non-disclosed commercial
arrangement (simple discount). Some aspects of the model-
ling have been updated since TA539, including unit costs, to
reflect 2017/2018 prices and present more robust unit cost
data; MAIC analyses, to include more covariates following
engagement with clinicians; and adverse events, to account
for occurrence of one event based on reported rates, rather
than assuming occurrence of multiple events during treat-
ments, as per NICE Economic Review Group analyses in
TA539.
Base case results were presented in Euros alongside GBP,
based on adjustment using purchasing power parity rates to
aid cross country comparisons. However, these should be
interpreted with extreme caution given country-specific
health systems, payment mechanisms, drug reimbursement
procedures and assessment bodies and specific treatment
costs across jurisdictions, including the impact of negotia-
tions and discounts. Evaluations based on local costs should
be conducted to determine cost-effectiveness.5. Conclusion
Based on these analyses it can be concluded that [177Lu]Lu-
DOTA-TATE is likely to be a cost-effective treatment option
compared to alternatives used in GEP-NET patients from an
England NHS perspective. Performed sensitivity analyses
demonstrate the robustness of cost-effectiveness estimates to
input parameter uncertainty.
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